Cancer journal最新文献_第2页

Risk Stratification in Myeloma: Defining Precision in the Genomic Era. 骨髓瘤的风险分层：定义基因组时代的精确性。

IF 2.1 4区医学

Cancer journal Pub Date : 2026-09-01 Epub Date: 2026-09-25 DOI: 10.1097/PPO.0000000000000844

Anaïs Schavgoulidze, Jill Corre

{"title":"Risk Stratification in Myeloma: Defining Precision in the Genomic Era.","authors":"Anaïs Schavgoulidze, Jill Corre","doi":"10.1097/PPO.0000000000000844","DOIUrl":"10.1097/PPO.0000000000000844","url":null,"abstract":"Multiple myeloma (MM) exhibits marked clinical heterogeneity, with outcomes ranging from long-term disease control to rapid progression. Accurate identification of high-risk patients is therefore essential. Over the past decades, cytogenetic abnormalities have emerged as key prognostic factors, leading to successive staging systems integrating genomic data. However, limitations in existing models and a lack of standardization have hindered optimal risk assessment. The recent Consensus Genomic Staging (CGS) provides a unified definition of high-risk disease, emphasizing TP53 alterations, biallelic 1p32 deletion, and combinations of intermediate-risk lesions. Validation studies confirm its prognostic value, while also highlighting residual heterogeneity and the concept of functional high-risk disease. Advances in next-generation sequencing, particularly whole-genome sequencing, offer deeper insight into genomic complexity and may further refine stratification. Integration of genomic profiling, gene expression, and minimal residual disease assessment is likely to enhance precision medicine. Ultimately, improved risk stratification is critical to guide risk-adapted therapeutic strategies and improve outcomes in multiple myeloma.","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"32 5","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Proteostasis as a Therapeutic Backbone: Proteasome Inhibitors and Emerging Regimens. 作为治疗支柱的蛋白酶体抑制剂和新出现的治疗方案。

IF 2.1 4区医学

Cancer journal Pub Date : 2026-09-01 Epub Date: 2026-09-25 DOI: 10.1097/PPO.0000000000000852

Yan Song, Poy Theprungsirikul, Annamaria Gulla, Kenneth C Anderson

{"title":"Proteostasis as a Therapeutic Backbone: Proteasome Inhibitors and Emerging Regimens.","authors":"Yan Song, Poy Theprungsirikul, Annamaria Gulla, Kenneth C Anderson","doi":"10.1097/PPO.0000000000000852","DOIUrl":"10.1097/PPO.0000000000000852","url":null,"abstract":"Multiple myeloma cells are uniquely dependent on proteostasis due to their exceptionally high immunoglobulin synthesis and protein turnover, rendering them hypersensitive to disruptions in protein degradation. Proteasome inhibitors targeting the 20 S catalytic core exploit this vulnerability and remain a therapeutic cornerstone in newly diagnosed and relapsed/refractory settings, anchoring both triplet and quadruplet regimens that incorporate anti-CD38 monoclonal antibodies, immunomodulatory agents, antibody-drug conjugates, and nuclear export inhibitors. Beyond the 20 S core, emerging targets, including the 19 S regulatory particle, deubiquitinating enzymes, and the E1-E2-E3 ubiquitination cascade, offer opportunities to intensify proteotoxic stress and overcome resistance. Targeted protein degradation platforms, including CELMoDs, proteolysis targeting chimeras, molecular glues, and proteasome cap-recruiting chimeras, further expand the therapeutic repertoire. Compensatory stress responses involving autophagy, the unfolded protein response, and the bone marrow microenvironment modulate therapeutic vulnerability. Collectively, these advances position proteostasis not as a single druggable target but as an integrated therapeutic network amenable to rational, biomarker-informed combination strategies in multiple myeloma.","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"32 5","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting Oncogenic Gene Fusions in Lung Cancer. 靶向肺癌的致癌基因融合。

IF 2.1 4区医学

Cancer journal Pub Date : 2026-07-01 Epub Date: 2026-07-24 DOI: 10.1097/PPO.0000000000000837

Yunan Nie, Frederick H Wilson

引用次数: 0

Lung Cancer Biomarker Testing: IHC, Tissue Genomics, Digital Pathology, and ctDNA. 肺癌生物标志物检测：免疫组化，组织基因组学，数字病理学和ctDNA。

IF 2.1 4区医学

Cancer journal Pub Date : 2026-07-01 Epub Date: 2026-07-24 DOI: 10.1097/PPO.0000000000000839

Humberto E Trejo Bittar, Sanja E Dacic

引用次数: 0

Medical Management of Non-Small Cell Lung Cancer Brain Metastases in the Modern Era. 现代非小细胞肺癌脑转移的医学处理

IF 2.1 4区医学

Cancer journal Pub Date : 2026-07-01 Epub Date: 2026-07-24 DOI: 10.1097/PPO.0000000000000840

Benjamin Y Lu, Sarah B Goldberg

引用次数: 0

A Quarter Century of Transformation: Integrating Molecular Stratification and Immune Modulation Across the Continuum of Non-Small-Cell Lung Cancer. 四分之一世纪的转化：整合非小细胞肺癌的分子分层和免疫调节。

IF 2.1 4区医学

Cancer journal Pub Date : 2026-07-01 Epub Date: 2026-07-24 DOI: 10.1097/PPO.0000000000000834

Amin H Nassar, Jad Halawi, Roy S Herbst

{"title":"A Quarter Century of Transformation: Integrating Molecular Stratification and Immune Modulation Across the Continuum of Non-Small-Cell Lung Cancer.","authors":"Amin H Nassar, Jad Halawi, Roy S Herbst","doi":"10.1097/PPO.0000000000000834","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000834","url":null,"abstract":"Non-small-cell lung cancer (NSCLC) has seen a paradigm shift over the past quarter century driven by systematic molecular characterization, the advent of targeted therapies, the implementation of low-dose CT screening, and the integration of immunotherapy across the disease continuum. Genomic profiling has defined oncogene-addicted subsets for which targeted agents now improve survival in both metastatic and resectable disease, while immune checkpoint inhibitors have displaced chemotherapy as first-line treatment for many patients without actionable drivers and have been incorporated into perioperative and consolidation strategies. Concurrently, adjuvant and consolidation tyrosine kinase inhibition has extended precision oncology into early-stage EGFR- and ALK-driven NSCLC. Here, we review pivotal therapeutic advances across metastatic, locally advanced, and early-stage disease; identify the need for more discriminating markers to refine treatment intensity and sequencing; and outline emerging approaches, including rational upfront combinations and the use of circulating tumor DNA to enable real-time, adaptive modulation of therapy in NSCLC.","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"32 4","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148583763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

KRAS-mutated Non-Small Cell Lung Cancer: Drugging the Undruggable. kras突变的非小细胞肺癌：治疗无法治愈的。

IF 2.1 4区医学

Cancer journal Pub Date : 2026-07-01 Epub Date: 2026-07-24 DOI: 10.1097/PPO.0000000000000842

Tämer El Saadany, Núria Aeschlimann, Adrian Sacher

{"title":"KRAS-mutated Non-Small Cell Lung Cancer: Drugging the Undruggable.","authors":"Tämer El Saadany, Núria Aeschlimann, Adrian Sacher","doi":"10.1097/PPO.0000000000000842","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000842","url":null,"abstract":"KRAS driver mutations have classically been considered undruggable by direct inhibitors in non-small cell lung cancer (NSCLC) as well as other solid tumors. However, recent advances have led to the first successful direct KRAS inhibitors, beginning with the development of KRASG12C inhibitors targeting the inactive GDP-bound state of KRAS. These initial KRASG12C (OFF) inhibitors demonstrated real but modest activity in KRASG12C-mutated mNSCLC. The development of more potent optimized KRASG12C (OFF) inhibitors has sought to improve upon the clinical activity of the initial raft of KRASG12C (OFF) inhibitors. Combination therapy with PD-1 inhibitors, as well as other classes of drugs, is also under intense investigation in NSCLC and other solid tumors. Nevertheless, primary and acquired resistance, as well as a variable and peculiar tendency to autoimmune hepatitis, have complicated efforts to develop this class of inhibitors in KRASG12C-mutated mNSCLC. In parallel, new direct inhibitor classes have emerged recently, including tri-complex ON-state inhibitors and dual-state ON/OFF inhibitors capable of targeting not only KRASG12C but also other KRAS mutations, as well as panKRAS and panRAS strategies. These agents have the potential to broaden the activity of initial KRASG12C (OFF) inhibitors and to avoid certain mechanisms of resistance and toxicity, but remain early in development with limited data. The KRAS therapeutic landscape is evolving rapidly, with many promising competing strategies each seeking to distinguish itself in an increasingly crowded therapeutic landscape.","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"32 4","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148583748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Basic and Translational Research Advances in NSCLC. 非小细胞肺癌基础与转化研究进展。

IF 2.1 4区医学

Cancer journal Pub Date : 2026-07-01 Epub Date: 2026-07-24 DOI: 10.1097/PPO.0000000000000841

Rajal Sharma, Katerina Politi

引用次数: 0

Early-Stage NSCLC: Novel Surgical Techniques and Neoadjuvant, Adjuvant, and Perioperative Therapies. 早期非小细胞肺癌：新的手术技术和新辅助、辅助和围手术期治疗。

IF 2.1 4区医学

Cancer journal Pub Date : 2026-07-01 Epub Date: 2026-07-24 DOI: 10.1097/PPO.0000000000000835

So Yeon Kim, Gavitt Woodard

{"title":"Early-Stage NSCLC: Novel Surgical Techniques and Neoadjuvant, Adjuvant, and Perioperative Therapies.","authors":"So Yeon Kim, Gavitt Woodard","doi":"10.1097/PPO.0000000000000835","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000835","url":null,"abstract":"Neoadjuvant and perioperative chemoimmunotherapy has transformed the treatment of tumors >4 cm or node-positive disease (stage II to IIIA, AJCC 8th edition) in non-small cell lung cancer (NSCLC). Compared with neoadjuvant chemotherapy alone, the addition of neoadjuvant immunotherapy to chemotherapy before resection has demonstrated improved pathologic complete response rate, event-free survival, and overall survival in stage II to IIIA NSCLC. The benefit observed with pathologic response after neoadjuvant therapy expands to include patients with stage II to IIIB NSCLC with sensitizing EGFR mutations with neoadjuvant osimertinib and is being evaluated with targeted therapies in additional actionable genomic drivers. Predictive biomarkers for pathologic response after neoadjuvant or perioperative therapies and biomarkers for disease recurrence, including evaluation of minimal residual disease through liquid biopsies, are under investigation to identify NSCLC patients who may have long-term survival with neoadjuvant or perioperative treatment. This chapter summarizes the current clinical landscape of neoadjuvant, perioperative, and adjuvant therapies and updates on surgical techniques for early-stage NSCLC.","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"32 4","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148583791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing the Care of Patients With Locally Advanced NSCLC With Multimodality Therapy. 多模式治疗优化局部晚期NSCLC患者的护理。

IF 2.1 4区医学

Cancer journal Pub Date : 2026-07-01 Epub Date: 2026-07-24 DOI: 10.1097/PPO.0000000000000836

Mohammed Mohammed, Neal S McCall, Kristin A Higgins

{"title":"Optimizing the Care of Patients With Locally Advanced NSCLC With Multimodality Therapy.","authors":"Mohammed Mohammed, Neal S McCall, Kristin A Higgins","doi":"10.1097/PPO.0000000000000836","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000836","url":null,"abstract":"Unresectable, locally advanced nonsmall cell lung cancer (LA‑NSCLC) accounts for ∼20% to 30% of newly diagnosed cases of NSCLC and remains associated with poor long‑term outcomes. Concurrent chemoradiotherapy (cCRT) has long been the therapeutic backbone for unresectable stage III disease, and the addition of consolidative durvalumab represents a major advance, significantly improving progression‑free and overall survival. Nonetheless, early progression and treatment‑related toxicity limit benefit for many patients, prompting investigation into alternative immunotherapy sequencing and escalation strategies. To date, randomized trials evaluating concurrent immune checkpoint blockade or intensified consolidation have not demonstrated additional survival benefit. In contrast, emerging precision‑medicine approaches-including consolidative targeted therapy for oncogene‑driven tumors-have yielded profound improvements in selected populations. Concurrently, advances in radiation delivery emphasize individualized strategies to optimize local control while minimizing toxicity. This review summarizes evolving systemic and radiation‑based approaches for LA‑NSCLC, highlighting current limitations and future directions to improve outcomes.","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"32 4","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148583799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0